[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chantal Csajka\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100532247","pharmacogenetic-testing-at-community-pharmacy-100532247",false,"NCT06210321","Pharmacogenetic Testing at Community Pharmacy","Randomised Controlled Study of the Efficacy and Acceptability of a Pharmacogenetic Test in the Management of Patients Treated With Escitalopram.","OffiGene","Inclusion Criteria:\n\n* Must consent to participate in the study,\n* Must sign consent,\n* Must be able to follow and understand the study procedures,\n* Initiation of escitalopram treatment for unipolar depression with or without anxiety\n\nExclusion Criteria:\n\n* Other condition than depression (such as panic disorder)\n* Escitalopram treatment already received\n* Not able to consent to participate in the study.","ALL","18 Years",{"count":20,"type":21},270,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to assess the clinical impact of reducing treatment failure rates after using genetic information targeting CYP2C19 in validating escitalopram prescription. 5 pharmacies in the canton of Vaud (Lausanne, Switzerland) will participate in the study.\n\nThe study will also explored the ability to perform the test in community pharmacy, physician and pharmacist approval of prescription changes, patient acceptance of the test and dose changes, the economic impact of the test, the association between genetic polymorphisms and therapeutic failures and the degree of satisfaction, barriers and facilitators by stakeholders.",[27],"Pharmacogenetic Testing",[29,30],"Community pharmacy","Escitalopram","NOT_YET_RECRUITING","2025-06-02",{"date":34,"type":35},"2025-06-05","ACTUAL",{"date":37,"type":21},"2025-08-15",{"date":39,"type":21},"2027-08-14",{"name":41,"class":42},"Chantal Csajka","OTHER",""]